Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)
China · Delayed Price · Currency is CNY 4.980
+0.060 (1.22%)
Jul 29, 2026, 3:04 PM CST
SHE:300158 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 2,678 | 2,783 | 2,971 | 3,626 | 3,729 | 5,094 |
Revenue Growth | -9.03% | -6.33% | -18.06% | -2.75% | -26.80% | 5.07% |
Gross Profit Gross Profit Growth | 1,372 | 1,394 | 1,159 | 1,796 | 1,834 | 3,036 |
Operating Income Operating Income Growth | -308.65 | -303.32 | -634.14 | -99.52 | -114.52 | 148.84 |
Net Income Net Income Growth | -303.26 | -301.06 | -1,329 | -43.98 | -51.29 | 2,617 |
Earnings Per Share EPS Growth | -0.30 | -0.30 | -1.30 | -0.04 | -0.05 | 2.55 |
EPS Growth | - | - | - | - | - | 898.98% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Pharmaceutical Production and Sales Pharmaceutical Production and Sales Growth | 3,201 |
Chinese Herbal Medicine Cultivation Chinese Herbal Medicine Cultivation Growth | 865.38 |
Research and Development Research and Development Growth | 104.94 |
Offset of Business Segment Offset of Business Segment Growth | -1,388 |
Total Total Growth | 2,783 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 782.89 | 1,002 | 1,579 | 2,249 | 2,740 | 5,692 |
Total Debt Total Debt Growth | 249.72 | 184.63 | 41.39 | 3.03 | 21.87 | 312.72 |
Net Cash (Debt) Net Cash Growth | 533.18 | 817.23 | 1,538 | 2,246 | 2,718 | 5,379 |
Net Cash Growth | -53.94% | -46.86% | -31.52% | -17.36% | -49.48% | 1003.25% |
Net Cash Per Share Net Cash Per Share Growth | 0.53 | 0.81 | 1.50 | 2.19 | 2.64 | 5.24 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -434.53 | -460.48 | -149.82 | -249.17 | 81.32 | 284.45 |
Capital Expenditures CapEx Growth | -172.11 | -179.12 | -298.48 | -116.21 | -145.81 | -151.66 |
Free Cash Flow Free Cash Flow Growth | -606.64 | -639.6 | -448.3 | -365.39 | -64.49 | 132.79 |
Free Cash Flow Growth | - | - | - | - | - | 249.58% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 51.24% | 50.08% | 39.00% | 49.54% | 49.20% | 59.60% |
Operating Margin | -11.53% | -10.90% | -21.34% | -2.74% | -3.07% | 2.92% |
Pretax Margin | -10.51% | -9.98% | -44.26% | -1.04% | -0.14% | 61.18% |
Profit Margin | -11.33% | -10.82% | -44.72% | -1.21% | -1.38% | 51.39% |
FCF Margin | -22.66% | -22.98% | -15.09% | -10.08% | -1.73% | 2.61% |
| Fiscal Year | FY 2021 |
|---|---|
| Period Ending | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 2.800 |
Dividend Per Share Growth | 3900.00% |
Dividend Yield | 44.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | - | 3.22 |
Forward PE | - | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 |
P/FCF Ratio | - | - | - | - | - | 63.37 |
PS Ratio | 1.85 | 2.07 | 1.46 | 1.91 | 2.05 | 1.65 |